SRPT$18.08
Chart
Performance
Key Stats
AI SRPT Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralSarepta Therapeutics exhibits a mixed profile with strong growth potential in its niche but faces significant volatility and challenges. Fundamentals are improving, but technicals show considerable weakness, and thematic tailwinds are specific to rare diseases.
Thematic
Sarepta operates in the high-potential but volatile rare disease therapeutics sector, with a focus on genetic therapies. The company's success is tied to the efficacy and market adoption of its specific treatments.
Fundamental
While Sarepta's revenue and net income have shown volatility, recent performance indicates a positive trend with improving profitability. The company maintains a solid balance sheet with manageable debt.
Technical
The stock has experienced a significant decline and is trading well below its 52-week high. Technical indicators suggest strong downward momentum and potential for further downside.
| Factor | Score |
|---|---|
| Biotechnology & Gene Therapy Advancements | 85 |
| Rare Disease Market Focus | 90 |
| Regulatory Landscape | 70 |
| Competition in Genetic Therapies | 50 |
| Partnerships and Collaborations | 75 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 80 |
| Growth | 85 |
| Balance Sheet Health | 40 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 40 |
| Short-Term Indicators | 30 |
AI Investing Checklist
Powered by LiveAIBullish Points (10)
Positive Cash Flow from Operations
The company's operating cash flow for the latest annual period (2024) was positive at $92.05M, indicating efficient generation of cash from core business activities.
Improving Cash Position
The company's end cash position has significantly increased from $444.01M in Q4 2023 to $1,118.59M in Q4 2024, demonstrating a strengthening liquidity buffer.
Bearish Points (12)
Negative TTM Net Income
The company has a negative Trailing Twelve Months (TTM) net income of $-254.85M, indicating overall unprofitability over the past year.
Significant Net Losses in Prior Years
The company has reported substantial net losses in prior annual periods, with net income of $-535.98M in 2023 and $-703.49M in 2022.
Calendar
August 2025
7
Next Earnings Date
H: $2.64
A: $1.17
L: $-0.06
H: 646.48M
A: 530.66M
L: 411.30M
Profile
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
48.04 USD
The 39 analysts offering 1 year price forecasts for SRPT have a max estimate of 110.00 and a min estimate of 10.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in Duchenne Muscular Dystrophy (DMD) with their gene therapy candidate (fordadistrogene movaparvovec), which directly competes with Sarepta's DMD gene therapy program.
Weight: 92
Direct competitor in the Duchenne Muscular Dystrophy (DMD) market with their approved treatments (Translarna, Emflaza), addressing the same patient population as Sarepta.
Weight: 90
A major player in the neuromuscular gene therapy space through AveXis (now a Novartis company) and its approved therapy Zolgensma for Spinal Muscular Atrophy (SMA), demonstrating expertise and market presence in genetic neuromuscular disorders.
Weight: 88
A leading company in RNA interference (RNAi) therapeutics, sharing a fundamental technological focus on RNA-targeted therapies for rare genetic diseases, similar to Sarepta's exon-skipping approach.